Simple blood test may predict lung cancer recurrence
NCT ID NCT07170046
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study will follow 100 lung cancer patients after surgery to see if levels of CEA and ctDNA in the blood can predict whether the cancer comes back. Participants will have regular blood tests and imaging over two years. The goal is to catch recurrence earlier and tailor follow-up care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict lung cancer recurrence earlier after surgery, allowing for more timely and personalized treatment adjustments.
- What could go wrong
- This is an observational study, not a treatment trial. It is small (100 people) and has not started recruiting yet, so results are uncertain and may not apply to all lung cancer patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer could spot cancers that standard scans overlook
- Can a conversation aid empower lung cancer patients?
- Can couples coping together ease the burden of advanced cancer?
- Can a custom toolkit help indigenous smokers spot lung cancer earlier?
- Study tests if teaching doctors and patients boosts lung cancer screening
- Could a vaccine stop lung cancer in smokers? early trial launches